Climb Bio (CLYM) Payables (2020 - 2026)

Climb Bio (CLYM) has 7 years of Payables data on file, last reported at $860000.0 in Q1 2026.

• Quarterly Payables rose 10.68% year-over-year to $860000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $860000.0 (up 10.68% YoY) and the FY2025 annual result came in at $2.3 million, up 221.84% from the prior year.
• Payables fell to $860000.0 in Q1 2026, from $2.3 million in the prior quarter.
• In the past five years, Payables ranged from a high of $2.3 million in Q4 2025 to a low of $66000.0 in Q4 2023.
• A 5-year average of $802117.6 and a median of $777000.0 in 2025 frame the typical range for Payables.
• Annual changes were most pronounced in 2022 — Payables jumped 4568.75% — and 2023, when it sank 91.2%.
• Tracing CLYM's Payables over 5 years: stood at $750000.0 in 2022, then slumped by 91.2% to $66000.0 in 2023, then surged by 968.18% to $705000.0 in 2024, then jumped by 221.84% to $2.3 million in 2025, then sank by 62.1% to $860000.0 in 2026.
• The last three Payables figures came in at $860000.0 (Q1 2026), $2.3 million (Q4 2025), and $477000.0 (Q3 2025), per Business Quant data.